TapewireFind a company

person · Reporting owner

PIMSTONE SIMON N.

Disclosed activity across 1 company

Tapewire entity
112810
SEC CIK
0001620084

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Xenon Pharmaceuticals Inc.XENE · Entity 2602DirectorJune 02, 2023June 02, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Xenon Pharmaceuticals Inc.

Report date June 02, 2023 · Filed June 02, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2033-06-01Direct18,475 Reported balance After 2023-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-02 · Grant · Acquired 18,475 · Balance 18,475

F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 02, 2023 Filed Jun 2, 2023 17:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 18,475 $0.00 Strike: $38.96 $0.00
Disclosure

SEC source: 0000950170-23-026169 · ownership.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,475

Underlying: Common Shares · 18,475 shares

Expires 2033-06-01

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $17.76 $0.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 19

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 45,000 shares

Expires 2025-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 9,318 $0.00 Strike: $7.69 $0.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 18

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,682

Underlying: Common Shares · 9,318 shares

Expires 2025-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 24,255 $38.78 $940,608.90
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 15

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.78 to $38.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 20,745 $38.53 $799,304.85
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 14

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,255

F8 · price: Represents the closing price of the Company's common shares on May 31, 2023 for purposes of net settlement calculations.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 45,000 $17.76 $799,200.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 13

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 7,458 $38.97 $290,638.26
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 12

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,860 $38.53 $71,665.80
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 11

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,458

F8 · price: Represents the closing price of the Company's common shares on May 31, 2023 for purposes of net settlement calculations.

Read SEC document
June 01, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 9,318 $7.69 $71,655.42
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 10

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,318

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $17.76 $0.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 17

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Shares · 50,000 shares

Expires 2025-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 29,835 $0.00 Strike: $9.85 $0.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · derivative · entry 16

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 29,835 shares

Expires 2024-01-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F10 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 26,856 $38.69 $1,039,058.64
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 9

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 23,144 $38.37 $888,035.28
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 8

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,856

F5 · price: Represents the closing price of the Company's common shares on May 30, 2023 for purposes of net settlement calculations.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 50,000 $17.76 $888,000.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 7

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 23,670 $38.81 $918,632.70
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 6

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.66 to $39.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 6,165 $38.37 $236,551.05
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 5

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,670

F5 · price: Represents the closing price of the Company's common shares on May 30, 2023 for purposes of net settlement calculations.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 29,835 $9.85 $293,874.75
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 4

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 12,000 $38.53 $462,360.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.20 to $38.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
May 30, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 19,000 $39.90 $758,100.00
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
May 30, 2023 Filed Jun 1, 2023 19:25 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 18,006 $38.63 $695,571.78
Disclosure

SEC source: 0000950170-23-025802 · ownership.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,000

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $39.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 30,864 $0.00 Strike: $2.59 $0.00
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · derivative · entry 8

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 30,864 shares

Expires 2023-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F5 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 41,152 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · derivative · entry 7

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 41,152 shares

Expires 2023-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F5 · derivative.exercise_date: The shares subject to the options are fully vested and exercisable.

F6 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 8,242 $36.94 $304,459.48
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 6

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,006

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,618 $37.13 $60,076.34
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 5

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,248

F2 · price: Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 30,864 $2.59 $79,937.76
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 4

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 10,990 $37.01 $406,739.90
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,002

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 2,160 $37.13 $80,200.80
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,992

F2 · price: Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations.

Read SEC document
March 07, 2023 Filed Mar 9, 2023 18:21 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 41,152 $2.68 $110,287.36
Disclosure

SEC source: 0001209191-23-017636 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,152

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
August 16, 2022 Filed Aug 16, 2022 17:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 20,000 $38.87 $777,400.00
Disclosure

SEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 6

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.70 to $39.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 16, 2022 Filed Aug 16, 2022 17:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 32,058 $38.29 $1,227,500.82
Disclosure

SEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 5

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,000

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.6431 to $38.6033, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 15, 2022 Filed Aug 16, 2022 17:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 33,942 $37.76 $1,281,649.92
Disclosure

SEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 4

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,058

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.5022 to $38.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 12, 2022 Filed Aug 16, 2022 17:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 1,000 $39.15 $39,150.00
Disclosure

SEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 3

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,000

Read SEC document
August 12, 2022 Filed Aug 16, 2022 17:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 47,000 $38.60 $1,814,200.00
Disclosure

SEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 2

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,000

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.1397 to $39.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
August 12, 2022 Filed Aug 16, 2022 17:31 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 43,135 $37.91 $1,635,247.85
Disclosure

SEC source: 0001209191-22-046015 · doc4.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.1353 to $38.1084, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 28, 2022 Filed Jun 29, 2022 17:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $30.11 $0.00
Disclosure

SEC source: 0001209191-22-039837 · doc4.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2032-06-27

F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 16:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $30.01 $0.00
Disclosure

SEC source: 0001209191-22-018457 · doc4.xml · derivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director · Executive Chair

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Shares · 25,000 shares

Expires 2032-03-09

F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Read SEC document
March 08, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.50 $76,250.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 19

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,135

Read SEC document
March 08, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.55 $76,375.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 18

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,635

F11 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.55 to $30.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Read SEC document
March 08, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.20 $75,500.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 17

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,135

Read SEC document
March 08, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.10 $75,250.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 16

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,635

Read SEC document
March 08, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $3.80 $9,500.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 15

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,135

F10 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 08, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,051 $30.60 $62,760.60
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 14

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,635

Read SEC document
March 08, 2022 Filed Mar 8, 2022 21:41 UTC Amendment Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.80 $77,000.00
Disclosure

SEC source: 0001209191-22-017418 · doc4a.xml · nonDerivative · entry 1

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,135

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 20,576 $0.00 Strike: $3.67 $0.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · derivative · entry 21

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 20,576 shares

Expires 2022-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F12 · derivative.exercise_date: 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date.

F13 · derivative.expiration_date: Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.55 $76,375.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 13

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,686

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 7,500 $30.50 $228,750.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 12

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,186

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,500 $30.52 $76,300.00
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 11

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,686

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 4,516 $30.44 $137,467.04
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 10

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,186

F9 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.40 to $30.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 4,516 $30.45 $137,512.20
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 9

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,702

F8 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4100 to $30.4750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 19:58 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 4,517 $30.49 $137,723.33
Disclosure

SEC source: 0001209191-22-017341 · doc4.xml · nonDerivative · entry 8

PIMSTONE SIMON N. · CIK 0001620084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,218

F7 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.480 to $30.645, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.